The ubiquitin-proteasome system in cardiac dysfunction

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1782, Issue 12, 2008, Pages 749-763

  Mearini, Giulia ^a   Schlossarek, Saskia ^a   Willis, Monte S ^b,c   Carrier, Lucie ^a,d,e  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d INSERM   (France)

^e SORBONNE UNIVERSITÉ   (France)

Author keywords

Autophagy; Cardiac disease; Cardiomyopathy; Ubiquitin proteasome system

Indexed keywords

ATROGIN 1; CELL PROTEIN; CHAPERONE; MEMBRANE PROTEIN; MUSCLE PROTEIN; MUSCLE RING FINGER 1 PROTEIN; NUCLEAR PROTEIN; PROTEASOME; PROTEIN DERIVATIVE; SECRETORY PROTEIN; UBIQUITIN; UBIQUITIN PROTEIN LIGASE;

AUTOPHAGY; CARDIOMYOPATHY; CELL FUNCTION; CELL ORGANELLE; CELL PROLIFERATION; CELL STRESS; CELL SURVIVAL; ENDOCYTOSIS; ENDOPLASMIC RETICULUM; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART HYPERTROPHY; HEART MUSCLE ISCHEMIA; HOMEOSTASIS; HUMAN; LYSOSOME; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN QUALITY; PROTEIN STABILITY; REPERFUSION INJURY; REVIEW; UBIQUITINATION;

ANIMALS; HEART DISEASES; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 56949095293     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2008.06.009     Document Type: Review

References (197)

1. Ciechanover A. The ubiquitin proteolytic system: from a vague idea, through basic mechanisms, and onto human diseases and drug targeting. Neurology 66 (2006) S7-S19
2. Koegl M., Hoppe T., Schlenker S., Ulrich H.D., Mayer T.U., and Jentsch S. A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell 96 (1999) 635-644
3. Wang X., and Robbins J. Heart failure and protein quality control. Circ. Res. 99 (2006) 1315-1328
4. Glickman M.H., and Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82 (2002) 373-428
5. Obsil T., and Obsilova V. Structure/function relationships underlying regulation of FOXO transcription factors. Oncogene 27 (2008) 2263-2275
6. Grossman S.R., Deato M.E., Brignone C., Chan H.M., Kung A.L., Tagami H., Nakatani Y., and Livingston D.M. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 300 (2003) 342-344
7. Gomes M.D., Lecker S.H., Jagoe R.T., Navon A., and Goldberg A.L. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 14440-14445
8. Bodine S.C., Latres E., Baumhueter S., Lai V.K., Nunez L., Clarke B.A., Poueymirou W.T., Panaro F.J., Na E., Dharmarajan K., Pan Z.Q., Valenzuela D.M., DeChiara T.M., Stitt T.N., Yancopoulos G.D., and Glass D.J. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294 (2001) 1704-1708
9. Bai C., Sen P., Hofmann K., Ma L., Goebl M., Harper J.W., and Elledge S.J. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell 86 (1996) 263-274
10. Cenciarelli C., Chiaur D.S., Guardavaccaro D., Parks W., Vidal M., and Pagano M. Identification of a family of human F-box proteins. Curr. Biol. 9 (1999) 1177-1179
11. Cardozo T., and Pagano M. The SCF ubiquitin ligase: insights into a molecular machine. Nat. Rev. Mol. Cell. Biol. 5 (2004) 739-751
12. Doyle D.A., Lee A., Lewis J., Kim E., Sheng M., and MacKinnon R. Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ. Cell 85 (1996) 1067-1076
13. Li H.H., Kedar V., Zhang C., McDonough H., Arya R., Wang D.Z., and Patterson C. Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. J. Clin. Invest. 114 (2004) 1058-1071
14. Sandri M., Sandri C., Gilbert A., Skurk C., Calabria E., Picard A., Walsh K., Schiaffino S., Lecker S.H., and Goldberg A.L. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117 (2004) 399-412
15. Stitt T.N., Drujan D., Clarke B.A., Panaro F., Timofeyva Y., Kline W.O., Gonzalez M., Yancopoulos G.D., and Glass D.J. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell. 14 (2004) 395-403
16. Bodine S.C., Stitt T.N., Gonzalez M., Kline W.O., Stover G.L., Bauerlein R., Zlotchenko E., Scrimgeour A., Lawrence J.C., Glass D.J., and Yancopoulos G.D. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat. Cell. Biol. 3 (2001) 1014-1019
17. Li H.H., Willis M.S., Lockyer P., Miller N., McDonough H., Glass D.J., and Patterson C. Atrogin-1 inhibits Akt-dependent cardiac hypertrophy in mice via ubiquitin-dependent coactivation of Forkhead proteins. J. Clin. Invest. 117 (2007) 3211-3223
18. Lamothe B., Besse A., Campos A.D., Webster W.K., Wu H., and Darnay B.G. Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of I kappa B kinase activation. J. Biol. Chem. 282 (2007) 4102-4112
19. Tintignac L.A., Lagirand J., Batonnet S., Sirri V., Leibovitch M.P., and Leibovitch S.A. Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase. J. Biol. Chem. 280 (2005) 2847-2856
20. Joazeiro C.A., and Weissman A.M. RING finger proteins: mediators of ubiquitin ligase activity. Cell 102 (2000) 549-552
21. Reymond A., Meroni G., Fantozzi A., Merla G., Cairo S., Luzi L., Riganelli D., Zanaria E., Messali S., Cainarca S., Guffanti A., Minucci S., Pelicci P.G., and Ballabio A. The tripartite motif family identifies cell compartments. Embo J. 20 (2001) 2140-2151
22. Meroni G., and Diez-Roux G. TRIM/RBCC, a novel class of 'single protein RING finger' E3 ubiquitin ligases. Bioessays 27 (2005) 1147-1157
23. Spencer J.A., Eliazer S., Ilaria Jr. R.L., Richardson J.A., and Olson E.N. Regulation of microtubule dynamics and myogenic differentiation by MURF, a striated muscle RING-finger protein. J. Cell. Biol. 150 (2000) 771-784
24. Centner T., Yano J., Kimura E., McElhinny A.S., Pelin K., Witt C.C., Bang M.L., Trombitas K., Granzier H., Gregorio C.C., Sorimachi H., and Labeit S. Identification of muscle specific ring finger proteins as potential regulators of the titin kinase domain. J. Mol. Biol. 306 (2001) 717-726
25. McElhinny A.S., Kakinuma K., Sorimachi H., Labeit S., and Gregorio C.C. Muscle-specific RING finger-1 interacts with titin to regulate sarcomeric M-line and thick filament structure and may have nuclear functions via its interaction with glucocorticoid modulatory element binding protein-1. J. Cell. Biol. 157 (2002) 125-136
26. McElhinny A.S., Perry C.N., Witt C.C., Labeit S., and Gregorio C.C. Muscle-specific RING finger-2 (MURF-2) is important for microtubule, intermediate filament and sarcomeric M-line maintenance in striated muscle development. J. Cell. Sci. 117 (2004) 3175-3188
27. Lange S., Xiang F., Yakovenko A., Vihola A., Hackman P., Rostkova E., Kristensen J., Brandmeier B., Franzen G., Hedberg B., Gunnarsson L.G., Hughes S.M., Marchand S., Sejersen T., Richard I., Edstrom L., Ehler E., Udd B., and Gautel M. The kinase domain of titin controls muscle gene expression and protein turnover. Science 308 (2005) 1599-1603
28. Witt S.H., Granzier H., Witt C.C., and Labeit S. MURF-1 and MURF-2 target a specific subset of myofibrillar proteins redundantly: towards understanding MURF-dependent muscle ubiquitination. J. Mol. Biol. 350 (2005) 713-722
29. Kedar V., McDonough H., Arya R., Li H.H., Rockman H.A., and Patterson C. Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 18135-18140
30. Witt C.C., Witt S.H., Lerche S., Labeit D., Back W., and Labeit S. Cooperative control of striated muscle mass and metabolism by MuRF1 and MuRF2. Embo J. 27 (2008) 350-360
31. Arya R., Kedar V., Hwang J.R., McDonough H., Li H.H., Taylor J., and Patterson C. Muscle ring finger protein-1 inhibits PKC{epsilon} activation and prevents cardiomyocyte hypertrophy. J. Cell. Biol. 167 (2004) 1147-1159
32. Koyama S., Hata S., Witt C.C., Ono Y., Lerche S., Ojima K., Chiba T., Doi N., Kitamura F., Tanaka K., Abe K., Witt S.H., Rybin V., Gasch A., Franz T., Labeit S., and Sorimachi H. Muscle RING-Finger Protein-1 (MuRF1) as a connector of muscle energy metabolism and protein synthesis. J. Mol. Biol. 376 (2008) 1224-1236
33. Fielitz J., van Rooij E., Spencer J.A., Shelton J.M., Latif S., van der Nagel R., Bezprozvannaya S., de Windt L., Richardson J.A., Bassel-Duby R., and Olson E.N. Loss of muscle-specific RING-finger 3 predisposes the heart to cardiac rupture after myocardial infarction. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 4377-4382
34. Clarke B.A., Drujan D., Willis M.S., Murphy L.O., Corpina R.A., Burova E., Rakhilin S.V., Stitt T.N., Patterson C., Latres E., and Glass D.J. The E3 ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell. Metab. 6 (2007) 376-385
35. Fielitz J., Kim M.S., Shelton J.M., Latif S., Spencer J.A., Glass D.J., Richardson J.A., Bassel-Duby R., and Olson E.N. Myosin accumulation and striated muscle myopathy result from the loss of muscle RING finger 1 and 3. J. Clin. Invest. 117 (2007) 2486-2495
36. Zhang C., Xu Z., He X.R., Michael L.H., and Patterson C. CHIP, a cochaperone/ubiquitin ligase that regulates protein quality control, is required for maximal cardioprotection after myocardial infarction in mice. Am. J. Physiol. Heart. Circ. Physiol. 288 (2005) H2836-H2842
37. Rosser M.F., Washburn E., Muchowski P.J., Patterson C., and Cyr D.M. Chaperone functions of the E3 ubiquitin ligase CHIP. J. Biol. Chem. 282 (2007) 22267-22277
38. Dai Q., Zhang C., Wu Y., McDonough H., Whaley R.A., Godfrey V., Li H.H., Madamanchi N., Xu W., Neckers L., Cyr D., and Patterson C. CHIP activates HSF1 and confers protection against apoptosis and cellular stress. Embo J. 22 (2003) 5446-5458
39. Qian S.B., McDonough H., Boellmann F., Cyr D.M., and Patterson C. CHIP-mediated stress recovery by sequential ubiquitination of substrates and Hsp70. Nature 440 (2006) 551-555
40. Esser C., Scheffner M., and Hohfeld J. The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation. J. Biol. Chem. 280 (2005) 27443-27448
41. Aravind L., and Koonin E.V. The U box is a modified RING finger-a common domain in ubiquitination. Curr. Biol. 10 (2000) R132-R134
42. Giordano F.J. Oxygen, oxidative stress, hypoxia, and heart failure. J. Clin. Invest. 115 (2005) 500-508
43. Semenza G.L. HIF-1 and mechanisms of hypoxia sensing. Curr. Opin. Cell. Biol. 13 (2001) 167-171
44. Haupt Y., Maya R., Kazaz A., and Oren M. Mdm2 promotes the rapid degradation of p53. Nature 387 (1997) 296-299
45. Shenoy S.K., McDonald P.H., Kohout T.A., and Lefkowitz R.J. Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin. Science 294 (2001) 1307-1313
46. Tian L.F., Li H.Y., Jin B.F., Pan X., Man J.H., Zhang P.J., Li W.H., Liang B., Liu H., Zhao J., Gong W.L., Zhou T., and Zhang X.M. MDM2 interacts with and downregulates a sarcomeric protein, TCAP. Biochem. Biophys. Res. Commun. 345 (2006) 355-361
47. Nastasi T., Bongiovanni A., Campos Y., Mann L., Toy J.N., Bostrom J., Rottier R., Hahn C., Conaway J.W., Harris A.J., and D'Azzo A. Ozz-E3, a muscle-specific ubiquitin ligase, regulates beta-catenin degradation during myogenesis. Dev. Cell. 6 (2004) 269-282
48. Kile B.T., Schulman B.A., Alexander W.S., Nicola N.A., Martin H.M., and Hilton D.J. The SOCS box: a tale of destruction and degradation. Trends. Biochem. Sci. 27 (2002) 235-241
49. Ingham R.J., Gish G., and Pawson T. The Nedd4 family of E3 ubiquitin ligases: functional diversity within a common modular architecture. Oncogene 23 (2004) 1972-1984
50. van Bemmelen M.X., Rougier J.S., Gavillet B., Apotheloz F., Daidie D., Tateyama M., Rivolta I., Thomas M.A., Kass R.S., Staub O., and Abriel H. Cardiac voltage-gated sodium channel Nav1.5 is regulated by Nedd4-2 mediated ubiquitination. Circ. Res. 95 (2004) 284-291
51. Jespersen T., Membrez M., Nicolas C.S., Pitard B., Staub O., Olesen S.P., Baro I., and Abriel H. The KCNQ1 potassium channel is down-regulated by ubiquitylating enzymes of the Nedd4/Nedd4-like family. Cardiovasc. Res. 74 (2007) 64-74
52. Kudryashova E., Kudryashov D., Kramerova I., and Spencer M.J. Trim32 is a ubiquitin ligase mutated in limb girdle muscular dystrophy type 2H that binds to skeletal muscle myosin and ubiquitinates actin. J. Mol. Biol. 354 (2005) 413-424
53. Voges D., Zwickl P., and Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu. Rev. Biochem. 68 (1999) 1015-1068
54. Baumeister W., Walz J., Zuhl F., and Seemuller E. The proteasome: paradigm of a self-compartmentalizing protease. Cell 92 (1998) 367-380
55. Groll M., Bajorek M., Kohler A., Moroder L., Rubin D.M., Huber R., Glickman M.H., and Finley D. A gated channel into the proteasome core particle. Nat. Struct. Biol. 7 (2000) 1062-1067
56. Heinemeyer W., Ramos P.C., and Dohmen R.J. The ultimate nanoscale mincer: assembly, structure and active sites of the 20S proteasome core. Cell. Mol. Life. Sci. 61 (2004) 1562-1578
57. Meiners S., Ludwig A., Stangl V., and Stangl K. Proteasome inhibitors: poisons and remedies. Med. Res. Rev. 28 (2008) 309-327
58. Goldberg A.L., Cascio P., Saric T., and Rock K.L. The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol. Immunol. 39 (2002) 147-164
59. Gomes A.V., Zong C., Edmondson R.D., Li X., Stefani E., Zhang J., Jones R.C., Thyparambil S., Wang G.W., Qiao X., Bardag-Gorce F., and Ping P. Mapping the murine cardiac 26S proteasome complexes. Circ. Res. 99 (2006) 362-371
60. Groll M., Heinemeyer W., Jager S., Ullrich T., Bochtler M., Wolf D.H., and Huber R. The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 10976-10983
61. Unno M., Mizushima T., Morimoto Y., Tomisugi Y., Tanaka K., Yasuoka N., and Tsukihara T. The structure of the mammalian 20S proteasome at 2.75 A resolution. Structure 10 (2002) 609-618
62. Zong C., Gomes A.V., Drews O., Li X., Young G.W., Berhane B., Qiao X., French S.W., Bardag-Gorce F., and Ping P. Regulation of murine cardiac 20S proteasomes: role of associating partners. Circ. Res. 99 (2006) 372-380
63. Finley D., Tanaka K., Mann C., Feldmann H., Hochstrasser M., Vierstra R., Johnston S., Hampton R., Haber J., McCusker J., Silver P., Frontali L., Thorsness P., Varshavsky A., Byers B., Madura K., Reed S.I., Wolf D., Jentsch S., Sommer T., Baumeister W., Goldberg A., Fried V., Rubin D.M., Toh-e A., et al. Unified nomenclature for subunits of the Saccharomyces cerevisiae proteasome regulatory particle. Trends Biochem. Sci. 23 (1998) 244-245
64. Verma R., Aravind L., Oania R., McDonald W.H., Yates J.R., Koonin E.V., and Deshaies R.J. Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. Science 298 (2002) 611-615
65. Yao T., and Cohen R.E. A cryptic protease couples deubiquitination and degradation by the proteasome. Nature 419 (2002) 403-407
66. Xie Y., and Varshavsky A. RPN4 is a ligand, substrate, and transcriptional regulator of the 26S proteasome: a negative feedback circuit. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 3056-3061
67. Mannhaupt G., Schnall R., Karpov V., Vetter I., and Feldmann H. Rpn4p acts as a transcription factor by binding to PACE, a nonamer box found upstream of 26S proteasomal and other genes in yeast. FEBS Lett. 450 (1999) 27-34
68. Deveraux Q., Ustrell V., Pickart C., and Rechsteiner M. A 26S protease subunit that binds ubiquitin conjugates. J. Biol. Chem. 269 (1994) 7059-7061
69. Glickman M.H., Rubin D.M., Coux O., Wefes I., Pfeifer G., Cjeka Z., Baumeister W., Fried V.A., and Finley D. A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3. Cell 94 (1998) 615-623
70. Elsasser S., Chandler-Militello D., Muller B., Hanna J., and Finley D. Rad23 and Rpn10 serve as alternative ubiquitin receptors for the proteasome. J. Biol. Chem. 279 (2004) 26817-26822
71. Elsasser S., Gali R.R., Schwickart M., Larsen C.N., Leggett D.S., Muller B., Feng M.T., Tubing F., Dittmar G.A., and Finley D. Proteasome subunit Rpn1 binds ubiquitin-like protein domains. Nat. Cell. Biol. 4 (2002) 725-730
72. Hartmann-Petersen R., Seeger M., and Gordon C. Transferring substrates to the 26S proteasome. Trends Biochem. Sci. 28 (2003) 26-31
73. Smith D.M., Benaroudj N., and Goldberg A. Proteasomes and their associated ATPases: a destructive combination. J. Struct. Biol. 156 (2006) 72-83
74. Braun B.C., Glickman M., Kraft R., Dahlmann B., Kloetzel P.M., Finley D., and Schmidt M. The base of the proteasome regulatory particle exhibits chaperone-like activity. Nat. Cell. Biol. 1 (1999) 221-226
75. Strickland E., Hakala K., Thomas P.J., and DeMartino G.N. Recognition of misfolding proteins by PA700, the regulatory subcomplex of the 26S proteasome. J. Biol. Chem. 275 (2000) 5565-5572
76. Lam Y.A., Lawson T.G., Velayutham M., Zweier J.L., and Pickart C.M. A proteasomal ATPase subunit recognizes the polyubiquitin degradation signal. Nature 416 (2002) 763-767
77. Seong K.M., Baek J.H., Yu M.H., and Kim J. Rpn13p and Rpn14p are involved in the recognition of ubiquitinated Gcn4p by the 26S proteasome. FEBS Lett. 581 (2007) 2567-2573
78. Hirano Y., Hendil K.B., Yashiroda H., Iemura S., Nagane R., Hioki Y., Natsume T., Tanaka K., and Murata S. A heterodimeric complex that promotes the assembly of mammalian 20S proteasomes. Nature 437 (2005) 1381-1385
79. Zwickl P., Grziwa A., Puhler G., Dahlmann B., Lottspeich F., and Baumeister W. Primary structure of the Thermoplasma proteasome and its implications for the structure, function, and evolution of the multicatalytic proteinase. Biochemistry 31 (1992) 964-972
80. Coux O., Nothwang H.G., Silva Pereira I., Recillas Targa F., Bey F., and Scherrer K. Phylogenic relationships of the amino acid sequences of prosome (proteasome, MCP) subunits. Mol. Gen. Genet. 245 (1994) 769-780
81. Chen P., and Hochstrasser M. Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly. Cell 86 (1996) 961-972
82. Ramos P.C., Hockendorff J., Johnson E.S., Varshavsky A., and Dohmen R.J. Ump1p is required for proper maturation of the 20S proteasome and becomes its substrate upon completion of the assembly. Cell 92 (1998) 489-499
83. Gorbea C., Taillandier D., and Rechsteiner M. Assembly of the regulatory complex of the 26S proteasome. Mol. Biol. Rep. 26 (1999) 15-19
84. Murray D., Ben-Tal N., Honig B., and McLaughlin S. Electrostatic interaction of myristoylated proteins with membranes: simple physics, complicated biology. Structure 5 (1997) 985-989
85. Polevoda B., and Sherman F. Nalpha-terminal acetylation of eukaryotic proteins. J. Biol. Chem. 275 (2000) 36479-36482
86. Drews O., Wildgruber R., Zong C., Sukop U., Nissum M., Weber G., Gomes A.V., and Ping P. Mammalian proteasome subpopulations with distinct molecular compositions and proteolytic activities. Mol. Cell. Proteomics 6 (2007) 2021-2031
87. Kisselev A.F., and Goldberg A.L. Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates. Methods Enzymol. 398 (2005) 364-378
88. Menendez-Benito V., Heessen S., and Dantuma N.P. Monitoring of ubiquitin-dependent proteolysis with green fluorescent protein substrates. Methods Enzymol. 399 (2005) 490-511
89. Lindsten K., and Dantuma N.P. Monitoring the ubiquitin/proteasome system in conformational diseases. Ageing Res. Rev. 2 (2003) 433-449
90. Sarikas A., Carrier L., Schenke C., Doll D., Flavigny J., Lindenberg K.S., Eschenhagen T., and Zolk O. Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants. Cardiovasc. Res. 66 (2005) 33-44
91. Bence N.F., Sampat R.M., and Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292 (2001) 1552-1555
92. Bence N.F., Bennett E.J., and Kopito R.R. Application and analysis of the GFPu family of ubiquitin-proteasome system reporters. Methods Enzymol. 399 (2005) 481-490
93. Dong X., Liu J., Zheng H., Glasford J.W., Huang W., Chen Q.H., Harden N.R., Li F., Gerdes A.M., and Wang X. In situ dynamically monitoring the proteolytic function of the ubiquitin-proteasome system in cultured cardiac myocytes. Am. J. Physiol. Heart Circ. Physiol. 287 (2004) H1417-H1425
94. Lindsten K., Menendez-Benito V., Masucci M.G., and Dantuma N.P. A transgenic mouse model of the ubiquitin/proteasome system. Nature Biotechnology 21 (2003) 897-902
95. Kumarapeli A.R., Horak K.M., Glasford J.W., Li J., Chen Q., Liu J., Zheng H., and Wang X. A novel transgenic mouse model reveals deregulation of the ubiquitin-proteasome system in the heart by doxorubicin. Faseb. J. 19 (2005) 2051-2053
96. Hein S., Arnon E., Kostin S., Schonburg M., Elsasser A., Polyakova V., Bauer E.P., Klovekorn W.P., and Schaper J. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 107 (2003) 984-991
97. Tsukamoto O., Minamino T., Okada K., Shintani Y., Takashima S., Kato H., Liao Y., Okazaki H., Asai M., Hirata A., Fujita M., Asano Y., Yamazaki S., Asanuma H., Hori M., and Kitakaze M. Depression of proteasome activities during the progression of cardiac dysfunction in pressure-overloaded heart of mice. Biochem. Biophys. Res. Commun. 340 (2006) 1125-1133
98. Weekes J., Morrison K., Mullen A., Wait R., Barton P., and Dunn M.J. Hyperubiquitination of proteins in dilated cardiomyopathy. Proteomics 3 (2003) 208-216
99. Powell S.R., Wang P., Katzeff H., Shringarpure R., Teoh C., Khaliulin I., Das D.K., Davies K.J., and Schwalb H. Oxidized and ubiquitinated proteins may predict recovery of postischemic cardiac function: essential role of the proteasome. Antioxid. Redox. Signal. 7 (2005) 538-546
100. Razeghi P., Sharma S., Ying J., Li Y.P., Stepkowski S., Reid M.B., and Taegtmeyer H. Atrophic remodeling of the heart in vivo simultaneously activates pathways of protein synthesis and degradation. Circulation 108 (2003) 2536-2541
101. Powell S.R., Samuel S.M., Wang P., Divald A., Thirunavukkarasu M., Koneru S., Wang X., and Maulik N. Upregulation of myocardial 11S-activated proteasome in experimental hyperglycemia. J. Mol. Cell. Cardiol. (2008)
102. Chen Q., Liu J.B., Horak K.M., Zheng H., Kumarapeli A.R., Li J., Li F., Gerdes A.M., Wawrousek E.F., and Wang X. Intrasarcoplasmic amyloidosis impairs proteolytic function of proteasomes in cardiomyocytes by compromising substrate uptake. Circ. Res. 97 (2005) 1018-1026
103. Liu J., Chen Q., Huang W., Horak K.M., Zheng H., Mestril R., and Wang X. Impairment of the ubiquitin-proteasome system in desminopathy mouse hearts. Faseb. J. 20 (2006) 362-364
104. Birks E.J., Latif N., Enesa K., Folkvang T., Luong L.A., Sarathchandra P., Khan M., Ovaa H., Terracciano C.M., Barton P.J., Yacoub M.H., and Evans P.C. Elevated p53 expression is associated with dysregulation of the ubiquitin-proteasome system in dilated cardiomyopathy. Cardiovasc. Res. (2008)
105. Depre C., Wang Q., Yan L., Hedhli N., Peter P., Chen L., Hong C., Hittinger L., Ghaleh B., Sadoshima J., Vatner D.E., Vatner S.F., and Madura K. Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy. Circulation 114 (2006) 1821-1828
106. Razeghi P., Baskin K.K., Sharma S., Young M.E., Stepkowski S., Essop M.F., and Taegtmeyer H. Atrophy, hypertrophy, and hypoxemia induce transcriptional regulators of the ubiquitin proteasome system in the rat heart. Biochem. Biophys. Res. Commun. 342 (2006) 361-364
107. Bulteau A.L., Lundberg K.C., Humphries K.M., Sadek H.A., Szweda P.A., Friguet B., and Szweda L.I. Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J. Biol. Chem. 276 (2001) 30057-30063
108. Farout L., Mary J., Vinh J., Szweda L.I., and Friguet B. Inactivation of the proteasome by 4-hydroxy-2-nonenal is site specific and dependant on 20S proteasome subtypes. Arch. Biochem. Biophys. 453 (2006) 135-142
109. Gurusamy N., Goswami S., Malik G., and Das D.K. Oxidative injury induces selective rather than global inhibition of proteasomal activity. J. Mol. Cell. Cardiol. 44 (2008) 419-428
110. Kostin S., Pool L., Elsasser A., Hein S., Drexler H.C., Arnon E., Hayakawa Y., Zimmermann R., Bauer E., Klovekorn W.P., and Schaper J. Myocytes die by multiple mechanisms in failing human hearts. Circ. Res. 92 (2003) 715-724
111. Yamamoto Y., Hoshino Y., Ito T., Nariai T., Mohri T., Obana M., Hayata N., Uozumi Y., Maeda M., Fujio Y., and Azuma J. Atrogin-1 ubiquitin ligase is upregulated by doxorubicin via p38-MAP kinase in cardiac myocytes. Cardiovasc. Res. 79 (2008) 89-96
112. Sharma S., Ying J., Razeghi P., Stepkowski S., and Taegtmeyer H. Atrophic remodeling of the transplanted rat heart. Cardiology 105 (2006) 128-136
113. Toth A., Nickson P., Qin L.L., and Erhardt P. Differential regulation of cardiomyocyte survival and hypertrophy by MDM2, an E3 ubiquitin ligase. J. Biol. Chem. 281 (2006) 3679-3689
114. Willis M.S., Ike C., Li L., Wang D.Z., Glass D.J., and Patterson C. Muscle ring finger 1, but not muscle ring finger 2, regulates cardiac hypertrophy in vivo. Circ. Res. 100 (2007) 456-459
115. Boheler K.R., Carrier L., Chassagne C., de la Bastie D., Mercadier J.J., and Schwartz K. Regulation of myosin heavy chain and actin isogenes expression during cardiac growth. Mol. Cell. Biochem. 104 (1991) 101-107
116. Schwartz K., Boheler K.R., de la Bastie D., Lompre A.M., and Mercadier J.J. Switches in cardiac muscle gene expression as a result of pressure and volume overload. Am. J. Physiol. 262 (1992) R364-R369
117. Schwartz K., Carrier L., Mercadier J.J., Lompré A.M., and Boheler K.R. Molecular phenotype of hypertrophied myocardium. Circulation 87 (1993) 5-10
118. Gordon E.E., Kira Y., and Morgan H.E. Aortic perfusion pressure, protein synthesis, and protein degradation. Circulation 75 (1987) I78-I80
119. Morgan H.E., Gordon E.E., Kira Y., Chua H.L., Russo L.A., Peterson C.J., McDermott P.J., and Watson P.A. Biochemical mechanisms of cardiac hypertrophy. Annu. Rev. Physiol. 49 (1987) 533-543
120. Okada K., Minamino T., Tsukamoto Y., Liao Y., Tsukamoto O., Takashima S., Hirata A., Fujita M., Nagamachi Y., Nakatani T., Yutani C., Ozawa K., Ogawa S., Tomoike H., Hori M., and Kitakaze M. Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction: possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis. Circulation 110 (2004) 705-712
121. Sano M., Minamino T., Toko H., Miyauchi H., Orimo M., Qin Y., Akazawa H., Tateno K., Kayama Y., Harada M., Shimizu I., Asahara T., Hamada H., Tomita S., Molkentin J.D., Zou Y., and Komuro I. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 446 (2007) 444-448
122. Balasubramanian S., Mani S., Shiraishi H., Johnston R.K., Yamane K., Willey C.D., Cooper IV G., Tuxworth W.J., and Kuppuswamy D. Enhanced ubiquitination of cytoskeletal proteins in pressure overloaded myocardium is accompanied by changes in specific E3 ligases. J. Mol. Cell. Cardiol. 41 (2006) 669-679
123. Lei L., Mason S., Liu D., Huang Y., Marks C., Hickey R., Jovin I.S., Pypaert M., Johnson R.S., and Giordano F.J. Hypoxia-inducible factor-dependent degeneration, failure, and malignant transformation of the heart in the absence of the von Hippel-Lindau protein. Mol. Cell. Biol. 28 (2008) 3790-3803
124. Divald A., and Powell S.R. Proteasome mediates removal of proteins oxidized during myocardial ischemia. Free Radic. Biol. Med. 40 (2006) 156-164
125. Ishii T., Sakurai T., Usami H., and Uchida K. Oxidative modification of proteasome: identification of an oxidation-sensitive subunit in 26S proteasome. Biochemistry 44 (2005) 13893-13901
126. Kubbutat M.H., Jones S.N., and Vousden K.H. Regulation of p53 stability by Mdm2. Nature 387 (1997) 299-303
127. Reid M.B. Response of the ubiquitin-proteasome pathway to changes in muscle activity. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288 (2005) R1423-R1431
128. Glass D.J. Skeletal muscle hypertrophy and atrophy signaling pathways. Int. J. Biochem. Cell. Biol. 37 (2005) 1974-1984
129. Depre C., Shipley G.L., Chen W., Han Q., Doenst T., Moore M.L., Stepkowski S., Davies P.J., and Taegtmeyer H. Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy. Nat. Med. 4 (1998) 1269-1275
130. Kobayashi S., Mao K., Zheng H., Wang X., Patterson C., O'Connell T.D., and Liang Q. Diminished GATA4 protein levels contribute to hyperglycemia-induced cardiomyocyte injury. J. Biol. Chem. 282 (2007) 21945-21952
131. Maron B.J., Gardin J.M., Flack J.M., Gidding S.S., Kurosaki T.T., and Bild D.E. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA study. Circulation 92 (1995) 785-789
132. Maron B.J., Ferrans V.J., and Roberts W.C. Ultrastructural features of degenerated cardiac muscle cells in patients with cardiac hypertrophy. Am. J. Pathol. 79 (1975) 387-434
133. Maron B.J., Nichols P.F., Pickle L.W., Wesley Y.E., and Mulvihill J.J. Patterns of inheritance in hypertrophic cardiomopathy. Assessment by M-mode and two-dimensional echocardiography. Am. J. Cardiol. 53 (1984) 1087-1094
134. Keller D.I., Carrier L., and Schwartz K. Genetics of familial hypertrophic cardiomyopathies and arrhythmias. Swiss Medical Weekly 132 (2002) 401-407
135. Richard P., Villard E., Charron P., and Isnard R. The genetic bases of cardiomyopathies. J. Am. Coll. Cardiol. 48 (2006) A79-A89
136. Richard P., Charron P., Carrier L., Ledeuil C., Cheav T., Pichereau C., Benaiche A., Isnard R., Dubourg O., Burban M., Gueffet J.P., Millaire A., Desnos M., Schwartz K., Hainque B., and Komajda M. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations and implications for molecular diagnosis strategy. Circulation 107 (2003) 2227-2232
137. Carrier L., Bonne G., and Schwartz K. Cardiac myosin binding protein C and hypertrophic cardiomyopathy. Trends Cardiovasc. Med. 8 (1998) 151-156
138. Carrier L. Cardiac myosin-binding protein C in the heart. Arch. Mal. Coeur. Vaiss. 100 (2007) 238-243
139. Fougerousse F., Delezoide A.L., Fiszman M.Y., Schwartz K., Beckmann J.S., and Carrier L. Cardiac myosin binding protein C gene is specifically expressed in heart during murine and human development. Circ. Res. 82 (1998) 130-133
140. Gautel M., Fürst D.O., Cocco A., and Schiaffino S. Isoform transitions of the myosin-binding protein C family in developing human and mouse muscles. Lack of isoform transcomplementation in cardiac muscle. Circ. Res. 82 (1998) 124-129
141. Cazorla O., Szilagyi S., Vignier N., Salazar G., Kramer E., Vassort G., Carrier L., and Lacampagne A. Length and protein kinase A modulations of myocytes in cardiac myosin binding protein C-deficient mice. Cardiovasc. Res. 69 (2006) 370-380
142. Pohlmann L., Kroger I., Vignier N., Schlossarek S., Kramer E., Coirault C., Sultan K.R., El-Armouche A., Winegrad S., Eschenhagen T., and Carrier L. Cardiac myosin-binding protein C is required for complete relaxation in intact myocytes. Circ. Res. 101 (2007) 928-938
143. Lecarpentier Y., Vignier N., Oliviero P., Guellich A., Carrier L., and Coirault C. Cardiac myosin-binding protein C modulates the tuning of the molecular motor in the heart. Biophys. J. 95 (2008) 1-9
144. Carrier L., Bonne G., Bährend E., Yu B., Richard P., Niel F., Hainque B., Cruaud C., Gary F., Labeit S., Bouhour J.B., Dubourg O., Desnos M., Hagège A.A., Trent R.J., Komajda M., and Schwartz K. Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy. Circ. Res. 80 (1997) 427-434
145. Moolman J.A., Reith S., Uhl K., Bailey S., Gautel M., Jeschke B., Fisher C., Ochs J., McKenna W.J., Klues H., and Vosberg H.P. A newly created splice donor site in exon 25 of the MyBP-C gene is responsible for inherited hypertrophic cardiomyopathy with incomplete disease penetrance. Circulation 101 (2000) 1396-1402
146. Rottbauer W., Gautel M., Zehelein J., Labeit S., Franz W.M., Fischer C., Vollrath B., Mall G., Dietz R., Kübler W., and Katus H.A. Novel splice donor site mutation in the cardiac myosin-binding protein-C gene in familial hypertrophic cardiomyopathy. Characterization of cardiac transcript and protein. J. Clin. Invest. 100 (1997) 475-482
147. Carrier L., Knoell R., Vignier N., Keller D.I., Bausero P., Prudhon B., Isnard R., Ambroisine M.L., Fiszman M., Ross J., Schwartz K., and Chien K.R. Asymmetric septal hypertrophy in heterozygous cMyBP-C null mice. Cardiovasc. Res. 63 (2004) 293-304
148. Eijssen L.M., van den Bosch B.J., Vignier N., Lindsey P.J., van den Burg C.M., Carrier L., Doevendans P.A., van der Vusse G.J., and Smeets H.J. Altered myocardial gene expression reveals possible maladaptive processes in heterozygous and homozygous cardiac myosin-binding protein C knockout mice. Genomics 91 (2008) 52-60
149. Flavigny J., Souchet M., Sébillon P., Berrebi-Bertrand I., Hainque B., Mallet A., Bril A., Schwartz K., and Carrier L.
150. Yang Q., Sanbe A., Osinska H., Hewett T.E., Klevitsky R., and Robbins J. In vivo modeling of myosin binding protein C familial hypertrophic cardiomyopathy. Circ. Res. 85 (1999) 841-847
151. Flavigny J., Robert P., Camelin J., Schwartz K., Carrier L., and Berebbi-Bertrand I. Biomolecular interactions between human recombinant b-MyHC and cMyBP-Cs implicated in familial hypertrophic cardiomyopathy. Cardiovasc. Res. 60 (2003) 388-396
152. Eble D.M., Spragia M.L., Ferguson A.G., and Samarel A.M. Sarcomeric myosin heavy chain is degraded by the proteasome. Cell. Tissue Res. 296 (1999) 541-548
153. Hughes S.E., and McKenna W.J. New insights into the pathology of inherited cardiomyopathy. Heart 91 (2005) 257-264
154. Heling A., Zimmermann R., Kostin S., Maeno Y., Hein S., Devaux B., Bauer E., Klövekorn W.P., Schlepper M., Schaper W., and Schaper J. Increased expression of cytoskeletal, linkage, and extracellular proteins in failing human myocardium. Circ. Res. 86 (2000) 846-853
155. Rappaport L., Contard F., Samuel J.L., Delcayre C., Marotte F., Tome F., and Fardeau M. Storage of phosphorylated desmin in a familial myopathy. FEBS Lett. 231 (1988) 421-425
156. Vicart P., Caron A., Guicheney P., Li Z., Prevost M.C., Faure A., Chateau D., Chapon F., Tome F., Dupret J.M., Paulin D., and Fardeau M. A missense mutation in the alphaB-crystallin chaperone gene causes a desmin-related myopathy. Nat. Genet. 20 (1998) 92-95
157. Wang X., Osinska H., Klevitsky R., Gerdes A.M., Nieman M., Lorenz J., Hewett T., and Robbins J. Expression of R120G-alphaB-crystallin causes aberrant desmin and alphaB-crystallin aggregation and cardiomyopathy in mice. Circ. Res. 89 (2001) 84-91
158. Sanbe A., Osinska H., Villa C., Gulick J., Klevitsky R., Glabe C.G., Kayed R., and Robbins J. Reversal of amyloid-induced heart disease in desmin-related cardiomyopathy. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 13592-13597
159. Sanbe A., Gulick J., Hanks M.C., Liang Q., Osinska H., and Robbins J. Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter. Circ. Res. 92 (2003) 609-616
160. Maloyan A., Gulick J., Glabe C.G., Kayed R., and Robbins J. Exercise reverses preamyloid oligomer and prolongs survival in alphaB-crystallin-based desmin-related cardiomyopathy. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 5995-6000
161. Liu J., Tang M., Mestril R., and Wang X. Aberrant protein aggregation is essential for a mutant desmin to impair the proteolytic function of the ubiquitin-proteasome system in cardiomyocytes. J. Mol. Cell. Cardiol. 40 (2006) 451-454
162. Purcell N.H., Tang G., Yu C., Mercurio F., DiDonato J.A., and Lin A. Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 6668-6673
163. Li Y., Ha T., Gao X., Kelley J., Williams D.L., Browder I.W., Kao R.L., and Li C. NF-kappaB activation is required for the development of cardiac hypertrophy in vivo. Am. J. Physiol. Heart. Circ. Physiol. 287 (2004) H1712-H1720
164. Gupta S., Young D., and Sen S. Inhibition of NF-kappaB induces regression of cardiac hypertrophy, independent of blood pressure control, in spontaneously hypertensive rats. Am. J. Physiol. Heart. Circ. Physiol. 289 (2005) H20-H29
165. Meiners S., Dreger H., Fechner M., Bieler S., Rother W., Gunther C., Baumann G., Stangl V., and Stangl K. Suppression of cardiomyocyte hypertrophy by inhibition of the ubiquitin-proteasome system. Hypertension 51 (2008) 302-308
166. Stansfield W.E., Tang R.H., Moss N.C., Baldwin A.S., Willis M.S., and Selzman C.H. Proteasome inhibition promotes regression of left ventricular hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 294 (2008) H645-H650
167. Bao J., Sato K., Li M., Gao Y., Abid R., Aird W., Simons M., and Post M.J. PR-39 and PR-11 peptides inhibit ischemia-reperfusion injury by blocking proteasome-mediated I kappa B alpha degradation. Am. J. Physiol. Heart Circ. Physiol. 281 (2001) H2612-H2618
168. Gao Y., Lecker S., Post M.J., Hietaranta A.J., Li J., Volk R., Li M., Sato K., Saluja A.K., Steer M.L., Goldberg A.L., and Simons M. Inhibition of ubiquitin-proteasome pathway-mediated I kappa B alpha degradation by a naturally occurring antibacterial peptide. J. Clin. Invest. 106 (2000) 439-448
169. Luss H., Schmitz W., and Neumann J. A proteasome inhibitor confers cardioprotection. Cardiovasc. Res. 54 (2002) 140-151
170. Pye J., Ardeshirpour F., McCain A., Bellinger D.A., Merricks E., Adams J., Elliott P.J., Pien C., Fischer T.H., Baldwin A.S., and Nichols T.C. Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 284 (2003) H919-H926
171. Stangl K., Gunther C., Frank T., Lorenz M., Meiners S., Ropke T., Stelter L., Moobed M., Baumann G., Kloetzel P.M., and Stangl V. Inhibition of the ubiquitin-proteasome pathway induces differential heat-shock protein response in cardiomyocytes and renders early cardiac protection. Biochem. Biophys. Res. Commun. 291 (2002) 542-549
172. Stansfield W.E., Moss N.C., Willis M.S., Tang R., and Selzman C.H. Proteasome inhibition attenuates infarct size and preserves cardiac function in a murine model of myocardial ischemia-reperfusion injury. Ann. Thorac. Surg. 84 (2007) 120-125
173. Onai Y., Suzuki J., Kakuta T., Maejima Y., Haraguchi G., Fukasawa H., Muto S., Itai A., and Isobe M. Inhibition of IkappaB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury. Cardiovasc. Res. 63 (2004) 51-59
174. Huang S., Patterson E., Yu X., Garrett M.W., De Aos I., and Kem D.C. Proteasome inhibition one hour following ischemia protects GRK2 and prevents malignant ventricular tachyarrhythmias and SCD in a model of myocardial infarction. Am. J. Physiol. Heart. Circ. Physiol. 3 (2008) H1298-1303
175. Penela P., Ruiz-Gomez A., Castano J.G., and Mayor F. Degradation of the G protein-coupled receptor kinase 2 by the proteasome pathway. J. Biol. Chem. 273 (1998) 35238-35244
176. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T., Harousseau J.L., Ben-Yehuda D., Lonial S., Goldschmidt H., Reece D., San-Miguel J.F., Blade J., Boccadoro M., Cavenagh J., Dalton W.S., Boral A.L., Esseltine D.L., Porter J.B., Schenkein D., and Anderson K.C. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352 (2005) 2487-2498
177. Orciuolo E., Buda G., Cecconi N., Galimberti S., Versari D., Cervetti G., Salvetti A., and Petrini M. Unexpected cardiotoxicity in haematological bortezomib treated patients. Br. J. Haematol. 138 (2007) 396-397
178. Berenson J.R., Matous J., Swift R.A., Mapes R., Morrison B., and Yeh H.S. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin. Cancer Res. 13 (2007) 1762-1768
179. Klionsky D.J., and Emr S.D. Autophagy as a regulated pathway of cellular degradation. Science 290 (2000) 1717-1721
180. Yorimitsu T., and Klionsky D.J. Autophagy: molecular machinery for self-eating. Cell Death Differ. 12 Suppl 2 (2005) 1542-1552
181. Yoshimori T. Autophagy: a regulated bulk degradation process inside cells. Biochem. Biophys. Res. Commun. 313 (2004) 453-458
182. Yoshimori T. Autophagy: paying Charon's toll. Cell 128 (2007) 833-836
183. Levine B., and Klionsky D.J. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev. Cell. 6 (2004) 463-477
184. Komatsu M., Waguri S., Ueno T., Iwata J., Murata S., Tanida I., Ezaki J., Mizushima N., Ohsumi Y., Uchiyama Y., Kominami E., Tanaka K., and Chiba T. Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. J. Cell. Biol. 169 (2005) 425-434
185. Kuma A., Hatano M., Matsui M., Yamamoto A., Nakaya H., Yoshimori T., Ohsumi Y., Tokuhisa T., and Mizushima N. The role of autophagy during the early neonatal starvation period. Nature 432 (2004) 1032-1036
186. Sybers H.D., Ingwall J., and DeLuca M. Autophagy in cardiac myocytes. Recent. Adv. Stud. Cardiac. Struct. Metab. 12 (1976) 453-463
187. Elsasser A., Vogt A.M., Nef H., Kostin S., Mollmann H., Skwara W., Bode C., Hamm C., and Schaper J. Human hibernating myocardium is jeopardized by apoptotic and autophagic cell death. J. Am. Coll. Cardiol. 43 (2004) 2191-2199
188. Knaapen M.W., Davies M.J., De Bie M., Haven A.J., Martinet W., and Kockx M.M. Apoptotic versus autophagic cell death in heart failure. Cardiovasc. Res. 51 (2001) 304-312
189. Saijo M., Takemura G., Koda M., Okada H., Miyata S., Ohno Y., Kawasaki M., Tsuchiya K., Nishigaki K., Minatoguchi S., Goto K., and Fujiwara H. Cardiomyopathy with prominent autophagic degeneration, accompanied by an elevated plasma brain natriuretic peptide level despite the lack of overt heart failure. Intern. Med. 43 (2004) 700-703
190. Shimomura H., Terasaki F., Hayashi T., Kitaura Y., Isomura T., and Suma H. Autophagic degeneration as a possible mechanism of myocardial cell death in dilated cardiomyopathy. Jpn. Circ. J. 65 (2001) 965-968
191. Yan L., Vatner D.E., Kim S.J., Ge H., Masurekar M., Massover W.H., Yang G., Matsui Y., Sadoshima J., and Vatner S.F. Autophagy in chronically ischemic myocardium. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 13807-13812
192. Nakai A., Yamaguchi O., Takeda T., Higuchi Y., Hikoso S., Taniike M., Omiya S., Mizote I., Matsumura Y., Asahi M., Nishida K., Hori M., Mizushima N., and Otsu K. The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat. Med. 13 (2007) 619-624
193. Martinet W., Knaapen M.W., Kockx M.M., and De Meyer G.R. Autophagy in cardiovascular disease. Trends Mol. Med. 13 (2007) 482-491
194. Mammucari C., Milan G., Romanello V., Masiero E., Rudolf R., Del Piccolo P., Burden S.J., Di Lisi R., Sandri C., Zhao J., Goldberg A.L., Schiaffino S., and Sandri M. FoxO3 controls autophagy in skeletal muscle in vivo. Cell. Metab. 6 (2007) 458-471
195. Skurk C., Izumiya Y., Maatz H., Razeghi P., Shiojima I., Sandri M., Sato K., Zeng L., Schiekofer S., Pimentel D., Lecker S., Taegtmeyer H., Goldberg A.L., and Walsh K. The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling. J. Biol. Chem. 280 (2005) 20814-20823
196. Zhao J., Brault J.J., Schild A., Cao P., Sandri M., Schiaffino S., Lecker S.H., and Goldberg A.L. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell. Metab. 6 (2007) 472-483
197. Lefkovwitz R.J., Rockman H.A., and Koch W.J. Catecholamines, cardiac b-adrenergic receptors, and heart failure. Circulation 101 (2000) 1634-1637